Robert W. Baird Trims Apellis Pharmaceuticals (NASDAQ:APLS) Target Price to $92.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its target price dropped by Robert W. Baird from $96.00 to $92.00 in a report released on Monday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 182.99% from the stock’s current price.

A number of other research analysts have also commented on the company. Wedbush increased their price objective on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a report on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Mizuho cut their target price on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, The Goldman Sachs Group lifted their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.53.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $32.51 on Monday. The business has a fifty day moving average of $37.87 and a 200-day moving average of $43.53. The firm has a market cap of $3.95 billion, a PE ratio of -9.40 and a beta of 0.88. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. Apellis Pharmaceuticals has a twelve month low of $31.00 and a twelve month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $199.70 million during the quarter, compared to the consensus estimate of $190.89 million. During the same period in the previous year, the firm posted ($1.02) earnings per share. The company’s revenue was up 110.2% on a year-over-year basis. On average, equities research analysts predict that Apellis Pharmaceuticals will post -1.29 EPS for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.80% of the stock is owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of APLS. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals during the first quarter worth $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Apellis Pharmaceuticals during the first quarter worth about $89,000. nVerses Capital LLC grew its holdings in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after buying an additional 2,100 shares in the last quarter. CWM LLC raised its position in Apellis Pharmaceuticals by 299.9% in the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after buying an additional 3,113 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in Apellis Pharmaceuticals in the 4th quarter valued at approximately $205,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).